Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with up to $1.8B in milestones.